Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period

Yung Chan, Bik Sai Bessie Tong, Pui Yan Ngan, Chi Sum Au Apex Dermatology Institute, Kowloon, Hong KongCorrespondence: Yung Chan Room 1103-06, 11/F Hong Kong Pacific Centre, 28 Hankow Road, Tsim Sha Tsui, Kowloon, Hong KongTel + 852 3703 3580Fax + 852 3702 0018Email info@apexdermhk.comBackground: In...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chan Y, Tong BSB, Ngan PY, Au CS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	chinese guselkumab interleukin-23 psoriasis real-world Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/f2d0e28fac9544468770dc5222741b78
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f2d0e28fac9544468770dc5222741b78
record_format	dspace
spelling	oai:doaj.org-article:f2d0e28fac9544468770dc5222741b782021-12-02T14:38:26ZEffectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period2230-326Xhttps://doaj.org/article/f2d0e28fac9544468770dc5222741b782021-06-01T00:00:00Zhttps://www.dovepress.com/effectiveness-of-il-23-inhibitor-guselkumab-in-real-world-chinese-pati-peer-reviewed-fulltext-article-PTThttps://doaj.org/toc/2230-326XYung Chan, Bik Sai Bessie Tong, Pui Yan Ngan, Chi Sum Au Apex Dermatology Institute, Kowloon, Hong KongCorrespondence: Yung Chan Room 1103-06, 11/F Hong Kong Pacific Centre, 28 Hankow Road, Tsim Sha Tsui, Kowloon, Hong KongTel + 852 3703 3580Fax + 852 3702 0018Email info@apexdermhk.comBackground: Interleukin-23 inhibitors are novel treatment options for psoriasis, and their efficacy and safety have been widely demonstrated in phase 3 clinical trials. Nonetheless, their real-world data remain limited, especially in Asia.Objective: To evaluate the real-world effectiveness of interleukin-23 inhibitor guselkumab in Chinese patients with psoriasis.Methods: In this retrospective single-center study, Chinese patients with psoriasis receiving a standard dose of guselkumab from November 2018 to May 2020 were included in the study cohort. Disease assessment was performed at baseline (Week 0), and at Week 4, 12, and 20 thereafter, using Psoriasis Area and Severity Index (PASI) score.Results: Data of 68 adult patients with psoriasis were retrieved for analysis. At Week 20, 72.1%/47.1% of the patients achieved PASI 90/100 response respectively, and 76.5% achieved a PASI score < 3. Baseline mean PASI score was 17.5, which significantly reduced to 2.0 at Week 20 (P=0.000). No previous use of biologics was a single significant factor associated with achieving PASI 90/100 and PASI score < 3 responses at Week 20 (all Ps< 0.05), while there were no statistically significant differences between males and females and body weight > 75 and ≤ 75 kg in achieving these responses (all Ps> 0.05). Adverse events were experienced by five patients (7.4%), and all were mild in severity.Conclusion: In this first real-world study on guselkumab among Chinese patients with psoriasis, this biologics was shown to be safe and effective in reaching an optimal clinical response up to 20 weeks.Keywords: Chinese, guselkumab, interleukin-23, psoriasis, real-worldChan YTong BSBNgan PYAu CSDove Medical Pressarticlechineseguselkumabinterleukin-23psoriasisreal-worldDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol Volume 11, Pp 53-58 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chinese guselkumab interleukin-23 psoriasis real-world Dermatology RL1-803
spellingShingle	chinese guselkumab interleukin-23 psoriasis real-world Dermatology RL1-803 Chan Y Tong BSB Ngan PY Au CS Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
description	Yung Chan, Bik Sai Bessie Tong, Pui Yan Ngan, Chi Sum Au Apex Dermatology Institute, Kowloon, Hong KongCorrespondence: Yung Chan Room 1103-06, 11/F Hong Kong Pacific Centre, 28 Hankow Road, Tsim Sha Tsui, Kowloon, Hong KongTel + 852 3703 3580Fax + 852 3702 0018Email info@apexdermhk.comBackground: Interleukin-23 inhibitors are novel treatment options for psoriasis, and their efficacy and safety have been widely demonstrated in phase 3 clinical trials. Nonetheless, their real-world data remain limited, especially in Asia.Objective: To evaluate the real-world effectiveness of interleukin-23 inhibitor guselkumab in Chinese patients with psoriasis.Methods: In this retrospective single-center study, Chinese patients with psoriasis receiving a standard dose of guselkumab from November 2018 to May 2020 were included in the study cohort. Disease assessment was performed at baseline (Week 0), and at Week 4, 12, and 20 thereafter, using Psoriasis Area and Severity Index (PASI) score.Results: Data of 68 adult patients with psoriasis were retrieved for analysis. At Week 20, 72.1%/47.1% of the patients achieved PASI 90/100 response respectively, and 76.5% achieved a PASI score < 3. Baseline mean PASI score was 17.5, which significantly reduced to 2.0 at Week 20 (P=0.000). No previous use of biologics was a single significant factor associated with achieving PASI 90/100 and PASI score < 3 responses at Week 20 (all Ps< 0.05), while there were no statistically significant differences between males and females and body weight > 75 and ≤ 75 kg in achieving these responses (all Ps> 0.05). Adverse events were experienced by five patients (7.4%), and all were mild in severity.Conclusion: In this first real-world study on guselkumab among Chinese patients with psoriasis, this biologics was shown to be safe and effective in reaching an optimal clinical response up to 20 weeks.Keywords: Chinese, guselkumab, interleukin-23, psoriasis, real-world
format	article
author	Chan Y Tong BSB Ngan PY Au CS
author_facet	Chan Y Tong BSB Ngan PY Au CS
author_sort	Chan Y
title	Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
title_short	Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
title_full	Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
title_fullStr	Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
title_full_unstemmed	Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
title_sort	effectiveness of il-23 inhibitor guselkumab in real-world chinese patients with psoriasis during a 20-week period
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/f2d0e28fac9544468770dc5222741b78
work_keys_str_mv	AT chany effectivenessofil23inhibitorguselkumabinrealworldchinesepatientswithpsoriasisduringa20weekperiod AT tongbsb effectivenessofil23inhibitorguselkumabinrealworldchinesepatientswithpsoriasisduringa20weekperiod AT nganpy effectivenessofil23inhibitorguselkumabinrealworldchinesepatientswithpsoriasisduringa20weekperiod AT aucs effectivenessofil23inhibitorguselkumabinrealworldchinesepatientswithpsoriasisduringa20weekperiod
_version_	1718390987682742272

Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period

Ejemplares similares